Breast Care A-Z · Condition · ADH

Atypical ductal hyperplasia

also: ADH, atypical hyperplasia, atypical lobular hyperplasia, ALH · pronounced hi-per-PLAY-zha

Atypical ductal hyperplasia (ADH) is a benign but higher-risk change in which abnormal cells build up inside a breast duct. It is not cancer, but because it can sit alongside something more significant, a small area is usually removed surgically to check it fully.

Quick answers

Is ADH cancer?

No. It's a benign change in the cells lining the breast ducts.

Will I need surgery?

Usually, yes. A small day-case excision to confirm the whole area is ADH only.

Why operate on something benign?

In 10–25%1 of cases, the rest of the area contains DCIS or invasive cancer the biopsy missed.

Atypical Ductal Hyperplasia -- Breastory Encyclopaedia Plate LX Plate covering ADH: B3 classification, cancer risk, management, and distinction from low-grade DCIS. ONCOLOGY · PRE-MALIGNANT LESIONS PLATE LX atypical ductal hyperplasia ADH · B3 lesion · lesion of uncertain malignant potential a non-obligate precursor lesion with features of low-grade DCIS that confers a 4-5-fold increased cancer risk FIG 01 -- Duct cross-section: Normal (left) | ADH (centre) | Low-grade DCIS (right) Normal single-layer epithelium ADH partial duct involvement DCIS complete duct involvement spectrum i -- partial involvement (<2 ducts or <2mm) ii -- architectural atypia (bridges, arcades) iii -- cytological atypia (enlarged nuclei) iv -- basement membrane intact v -- risk marker (not obligate precursor) Distinguishing ADH from DCIS ADH: <2 duct spaces OR <2mm extent DCIS: >=2 ducts AND >=2mm extent Criteria: Quantitative (Tavassoli / Page) Both: ER+, BM intact, cytological atypia Key: Quantitative -- not qualitative Management after B3/ADH diagnosis Core biopsy B3 Vacuum-assisted biopsy (upgrade ~20%) Excision biopsy ADH confirmed, clear margins sought Follow-up Annual mammo 5 yrs + chemoprevention FIG 02 -- ADH vs Low-grade DCIS: diagnostic comparison Feature ADH Low-grade DCIS Extent <2 duct spaces or <2mm >=2 ducts and >=2mm Cytology Mildly atypical More uniformly atypical Architecture Partial duct filling Complete filling ER status Usually ER+ Usually ER+ Basement membrane Intact Intact Classification B3 B5a Biopsy finding Often incidental May present with calcifications Upgrade rate (VAB) ~20% to DCIS/IDC N/A Cancer risk (5-yr) 4-5x general population Stage 0 cancer Management Excision + surveillance Excision + adjuvant FIG 03 -- B3 lesion types: risk and management Lesion Cancer risk Management ADH 4-5x relative risk VAB + excision ALH (atypical lobular) 4-5x VAB + surveillance FEA (flat epithelial) Uncertain VAB, may not need excision Classic LCIS 8-10x Risk surveillance Pleomorphic LCIS Higher Excision advised Papilloma with atypia ~20% upgrade Excision Radial scar with atypia ~20% upgrade Excision Phyllodes (borderline) Malignant potential Wide excision Mucocele-like + atypia Uncertain Excision FIG 04 -- Clinical pathway: ADH management 1 Calcifications on screening mammogram 2 Core biopsy 3 B3/ADH confirmed 4 VAB for upgrade assessment 5 Surgical excision if ADH on VAB 6 Annual surveillance + chemoprevention discussion FIG 05 -- Related procedures and considerations ADH on core biopsy Vacuum-assisted biopsy (upgrade) Surgical excision (B3) Tamoxifen chemoprevention Annual surveillance mammogram Genetic counselling (+ family history) FIG 06 -- Key statistics 4-5x increased cancer risk with ADH [1] ~20% upgrade to DCIS/cancer on excision [2] ~10% of screen-detected B3 lesions are ADH [3] Tamoxifen reduces risk by ~38% in ADH [4] References 1. Page DL et al. ADH and cancer risk. Cancer 1985 2. Forgeard C et al. Significance of ADH at core biopsy. Breast 2008 3. NHS BSP. Guidelines for B3 management 2022 4. Fisher B et al. NSABP P-1 tamoxifen. JNCI 1998 5. NICE NG101. Early breast cancer 2023 Clinically authored by Dr Fiona Tsang-Wright , FRCS (Gen Surg) GMC 4549831 · ORCID 0000-0003-4801-026X
Visual Reference · Atypical ductal hyperplasia
Open full size ↗
Definition
Atypical ductal hyperplasia (ADH) is a benign but atypical change in the cells lining the breast ducts — sitting between normal tissue and ductal carcinoma in situ — and is usually surgically excised because the whole specimen sometimes reveals a higher-risk change that the needle biopsy did not capture.
10–25% Upgrade rate to DCIS or invasive cancer on excision 1
≈ 4× Lifetime breast cancer risk vs general population 2
~50% Risk reduction from chemoprevention (tamoxifen / AIs) 4 5

Common questions The questions patients ask first

Is ADH cancer?
No. ADH is a benign atypical change, not a cancer6. The reason it is taken seriously is the upgrade rate — when the whole area is excised surgically, around 1 in 4 to 1 in 10 patients turn out to have DCIS or invasive cancer that the biopsy did not capture1. Excision confirms the diagnosis; the diagnosis itself is benign.
Why does ADH need surgery if it's benign?
Because the biopsy might not have captured the full picture. The biopsy samples a small fraction of the area7; the rest sometimes contains a higher-risk change that needs treatment3. Where surgery confirms ADH only, no further surgical treatment is needed.
Is ADH the same as DCIS?
They are on the same spectrum — both involve atypical cells in the duct lining6. The difference is how much of the duct system is involved: a small focus is ADH; a more extensive area is DCIS.
Will I get cancer in the future?
Most patients with ADH will not develop breast cancer in their lifetime — but the risk is higher than the population average (roughly 4× the population baseline)2. Annual mammograms and a chemoprevention discussion are part of the management plan after excision3.
Will my insurance cover the surgery?
Yes — surgical excision of ADH is a recognised clinical pathway and is covered by major UK insurers. Pre-authorisation depends on the procedure code and the indication; the PA can advise.

Atypical ductal hyperplasia (ADH) is a benign but atypical change in the cells lining the breast ducts — sitting between normal tissue and ductal carcinoma in situ — and is usually surgically excised because the whole specimen sometimes reveals a higher-risk change that the needle biopsy did not capture.

ADH is most often found incidentally on a biopsy taken for microcalcifications or another concerning imaging finding. The biopsy result of “ADH” is not cancer, but it is rarely the final answer — surgical excision of the whole area shows DCIS or invasive cancer in around 15–30% of cases1, which is why surgery is usually recommended even after a clear biopsy result3.

If excision is recommended The three possible outcomes

Surgical excision of the area where ADH was found
↓
75–90%
ADH only
The whole area was indeed ADH. Plan moves to surveillance plus a chemoprevention discussion.
10–25%
Upgrade to DCIS or invasive cancer
The biopsy missed a higher-risk change. Treatment plan adjusts; often further surgery and adjuvant treatment.
Few %
Borderline
Picture is intermediate. Case reviewed at MDT to agree the next step.

Source: 1

In more depth Where ADH sits on the duct-lining spectrum

Normal
UDH
ADH
DCIS
Invasive

Source: 6

On core biopsy, ADH is classified as a B3 lesion — a result of uncertain malignant potential under the RCPath/NHSBSP B1–B5 reporting system — which is why further sampling (VAE or excision) and MDT review are standard. Pathologists also describe changes on a continuum6 from normal duct lining, through usual ductal hyperplasia (extra cells, no clinical significance), to ADH (extra cells beginning to look abnormal), DCIS (definitely abnormal but confined to the duct), and invasive cancer (cells through the duct wall).

ADH and “low-grade DCIS” can be very similar under the microscope; the distinction depends on extent. A small focus is called ADH; a larger area of the same change is called DCIS.

The closely related atypical lobular hyperplasia (ALH) is the lobular equivalent — atypical changes in the lobules rather than the ducts. Management is similar in principle, though ALH is more often found alongside LCIS and managed in that context.

Clinical reasoning Why excision is usually recommended

The key clinical question with ADH is: does the biopsy capture the full picture? A core biopsy takes 3–6 small samples from the area of concern7. If those samples show ADH, the rest of the area might still contain a small focus of DCIS or even invasive cancer that the biopsy did not sample.

The “upgrade rate” — the chance that a biopsy of ADH turns out to have a higher-risk lesion when the whole area is sampled — is approximately 15–30% in UK series (around 1 in 4)1. Because that is non-trivial, current NHSBSP/ABS guidance recommends further sampling of the area where ADH was found3.

The operation Vacuum-assisted excision and surgical excision

In UK practice, vacuum-assisted excision (VAE) under imaging guidance is usually the first step for ADH on core biopsy — removing a larger tissue sample through a small skin nick, often as a local-anaesthetic procedure. Open surgical wide local excision is offered when VAE shows residual atypia, the lesion is unsuitable for VAE, imaging and pathology are discordant at MDT, or the patient prefers surgery. When open excision is needed, the operation is a small wide local excision, similar to a fibroadenoma excision:

  • Day-case under general anaesthetic.
  • The area is localised before surgery if the original lesion was visible only on imaging — see impalpable lesion localisation.
  • A small ellipse of breast tissue containing the area of concern is removed.
  • The specimen is sent to pathology for full examination.
  • The wound is closed with absorbable stitches under the skin.

Recovery is typically straightforward — most patients return to desk-based work within days, and full activity within a couple of weeks. The histology of the excised specimen comes back over a few working days.

Long term What ADH means for future risk

Even after surgical excision confirms ADH only, the diagnosis is not “back to baseline”:

  • ADH is associated with a roughly 4-fold increased lifetime risk of breast cancer compared to the general population2.
  • The future cancer risk applies to both breasts, not just the one where ADH was found2.
  • The risk is reduced — but not eliminated — by surgical excision of the index area.

The post-excision plan typically includes annual mammograms3, a discussion of chemoprevention (tamoxifen pre-menopausal or aromatase inhibitors post-menopausal — these reduce subsequent invasive cancer risk by around 50%45), and consideration of risk-reducing surgery only where ADH co-exists with other high-risk factors3.

In recent practice When surgery may not be needed

Recent evidence has questioned whether surgery is needed for every case of ADH. Some specific subgroups have very low upgrade rates (under 10%)1 and may be candidates for active surveillance rather than immediate excision. The specific criteria are evolving and decisions are made at MDT. For most patients with ADH on biopsy, excision remains the standard recommendation.

At consultation What to discuss with your surgeon

If your biopsy shows ADH, useful things to talk through include the reason for excision and the upgrade rate, what the small day-case operation involves, the surveillance and chemoprevention plan if the whole specimen confirms ADH only, the next steps if the specimen shows DCIS or invasive cancer, and whether family history or genetic testing should be explored — particularly in younger patients.

ADH is often found after a one-stop clinic biopsy. If you want an independent view of excision versus surveillance, a second-opinion consultation is appropriate.

Further reading

Sources & guidance

Every figure on this page is anchored to a published source. Tap a number in the text or below to jump to the reference.

  1. meta analysis Schiaffino S, Calabrese M, Melani EF, et al. Upgrade rate of percutaneously diagnosed pure atypical ductal hyperplasia: systematic review and meta-analysis of 6,458 lesions. Radiology. 2020 ;294(1):76–86 doi:10.1148/radiol.2019190748 Cited for: 10–25% upgrade rate; 75–90% ADH-only outcome; decision-tree percentages.
  2. cohort Hartmann LC, Degnim AC, Santen RJ, et al. Atypical hyperplasia of the breast — risk assessment and management options. New England Journal of Medicine. 2015 ;372(1):78–89 doi:10.1056/NEJMsr1407164 Cited for: ≈ 4× lifetime breast cancer risk; bilateral risk distribution.
  3. guideline National Institute for Health and Care Excellence (NICE). Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer (CG164). London: NICE. 2013 ;Last updated 2023 https://www.nice.org.uk/guidance/cg164 Cited for: UK standard recommendation for excision; annual mammographic surveillance; chemoprevention discussion; risk-reducing surgery thresholds.
  4. rct Cuzick J, Sestak I, Forbes JF, et al. Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. Lancet. 2014 ;383(9922):1041–1048 doi:10.1016/S0140-6736(13)62292-8 Cited for: ~50% chemoprevention risk reduction (aromatase inhibitors, post-menopausal).
  5. rct Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. Journal of the National Cancer Institute. 1998 ;90(18):1371–1388 doi:10.1093/jnci/90.18.1371 Cited for: ~50% chemoprevention risk reduction (tamoxifen, pre-menopausal).
  6. reference text WHO Classification of Tumours Editorial Board. Breast Tumours. WHO Classification of Tumours, 5th edition, vol. 2. Lyon: International Agency for Research on Cancer. 2019 https://tumourclassification.iarc.who.int/ Cited for: Duct-lining spectrum classification (Normal → UDH → ADH → DCIS → Invasive); ADH/DCIS distinction by extent.
  7. guidance Royal College of Radiologists. Guidance on screening and symptomatic breast imaging. 4th edition. London: RCR. 2019 https://www.rcr.ac.uk Cited for: Core biopsy technique (3–6 samples per lesion).